These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 30836381)

  • 1. Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia.
    Leucht S; Barabássy Á; Laszlovszky I; Szatmári B; Acsai K; Szalai E; Harsányi J; Earley W; Németh G
    Neuropsychopharmacology; 2019 Aug; 44(9):1589-1596. PubMed ID: 30836381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
    Addington DE; Pantelis C; Dineen M; Benattia I; Romano SJ
    J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI.
    Levine SZ; Rabinowitz J; Engel R; Etschel E; Leucht S
    Schizophr Res; 2008 Jan; 98(1-3):318-22. PubMed ID: 17949948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What does the PANSS mean?
    Leucht S; Kane JM; Kissling W; Hamann J; Etschel E; Engel RR
    Schizophr Res; 2005 Nov; 79(2-3):231-8. PubMed ID: 15982856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors.
    Fleischhacker W; Galderisi S; Laszlovszky I; Szatmári B; Barabássy Á; Acsai K; Szalai E; Harsányi J; Earley W; Patel M; Németh G
    Eur Psychiatry; 2019 May; 58():1-9. PubMed ID: 30738380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data.
    Earley W; Guo H; Daniel D; Nasrallah H; Durgam S; Zhong Y; Patel M; Barabássy Á; Szatmári B; Németh G
    Schizophr Res; 2019 Feb; 204():282-288. PubMed ID: 30172595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does clinical judgment of baseline severity and changes in psychopathology depend on the patient population? Results of a CGI and PANSS linking analysis in a naturalistic study.
    Schennach-Wolff R; Obermeier M; Seemüller F; Jäger M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Engel RR; Möller HJ; Riedel M
    J Clin Psychopharmacol; 2010 Dec; 30(6):726-31. PubMed ID: 21105273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial.
    Németh G; Laszlovszky I; Czobor P; Szalai E; Szatmári B; Harsányi J; Barabássy Á; Debelle M; Durgam S; Bitter I; Marder S; Fleischhacker WW
    Lancet; 2017 Mar; 389(10074):1103-1113. PubMed ID: 28185672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Equipercentile linking of the BPRS and the PANSS.
    Leucht S; Rothe P; Davis JM; Engel RR
    Eur Neuropsychopharmacol; 2013 Aug; 23(8):956-9. PubMed ID: 23433639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linking the PANSS, BPRS, and CGI: clinical implications.
    Leucht S; Kane JM; Etschel E; Kissling W; Hamann J; Engel RR
    Neuropsychopharmacology; 2006 Oct; 31(10):2318-25. PubMed ID: 16823384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
    Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
    JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
    Kane JM; Carson WH; Saha AR; McQuade RD; Ingenito GG; Zimbroff DL; Ali MW
    J Clin Psychiatry; 2002 Sep; 63(9):763-71. PubMed ID: 12363115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).
    Hermes ED; Sokoloff D; Stroup TS; Rosenheck RA
    J Clin Psychiatry; 2012 Apr; 73(4):526-32. PubMed ID: 22579152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone.
    Gharabawi GM; Lasser RA; Bossie CA; Zhu Y; Amador X
    Int Clin Psychopharmacol; 2006 Jul; 21(4):233-40. PubMed ID: 16687995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial.
    Durgam S; Starace A; Li D; Migliore R; Ruth A; Németh G; Laszlovszky I
    Schizophr Res; 2014 Feb; 152(2-3):450-7. PubMed ID: 24412468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapse in clinically stable adult patients with schizophrenia or schizoaffective disorder: evidence-based criteria derived by equipercentile linking and diagnostic test accuracy meta-analysis.
    Siafis S; Brandt L; McCutcheon RA; Gutwinski S; Schneider-Thoma J; Bighelli I; Kane JM; Arango C; Kahn RS; Fleischhacker WW; McGorry P; Carpenter WT; Falkai P; Hasan A; Marder SR; Schooler N; Engel RR; Honer WG; Buchanan RW; Davidson M; Weiser M; Priller J; Davis JM; Howes OD; Correll CU; Leucht S
    Lancet Psychiatry; 2024 Jan; 11(1):36-46. PubMed ID: 38043562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia.
    Davidson M; Saoud J; Staner C; Noel N; Luthringer E; Werner S; Reilly J; Schaffhauser JY; Rabinowitz J; Weiser M; Luthringer R
    Am J Psychiatry; 2017 Dec; 174(12):1195-1202. PubMed ID: 28750582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study.
    Zhong KX; Sweitzer DE; Hamer RM; Lieberman JA
    J Clin Psychiatry; 2006 Jul; 67(7):1093-103. PubMed ID: 16889453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying clinically meaningful symptom response cut-off values on the SANS in predominant negative symptoms.
    Levine SZ; Leucht S
    Schizophr Res; 2013 Apr; 145(1-3):125-7. PubMed ID: 23394742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.